The two companies look to develop regenerative medicine products to treat ischemic heart disease.
According to a release, the relationship was bolstered by the Catalyze Award that Cellular Logistics received, which will accelerate the development studies toward clinical-grade manufacturing of the company’s lead product, SolusTM.